 |
|
|
| |
STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Is Non-Inferior Compared to
Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes through Week 96
|
| |
| |
Reported by Jules Levin
54th Interscience Conference on Antimicrobial Agents and Chemotherapy
September 5-9, 2014
Washingtion DC, USA
C Cohen1, D Wohl2, M Cavassini3, K Henry4, M Bloch5, W Towner6, W Garner7, D Porter7, C Chien7, S De-Oertel7
1Comm Res Init of New England, Boston, MA; 2U North Carolina, Chapel Hill, NC; 3Ctr Hosp Univ Vaudois, Lausanne, Switzerland; 4Hennepin County Med Ctr, Minneapolis, MN; 5Holdsworth House, Darlinghurst, Australia; 6Kaiser, Los Angeles, CA; 7Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
